Close Menu

financial results

The firm also reported that 2016 preliminary revenues were up 14 percent, and that Nanosphere MDx platform revenues rose 32 percent.

Biopharma revenue grew from $14.1 million to $19 million in the quarter while clinical testing revenue declined from $12 million to $9.8 million.

The company said revenues from its clinical lab services rose 9 percent because of high demand for certain molecular diagnostic services.

Contributing to the revenue increase was a rise in in test and collection volume for its thyroid cancer diagnostics.

The firm offered a qualitative assessment of third quarter business activities, and announced a private placement and a US distribution deal with Thermo Fisher.

At its investor day presentation, the company will outline its strategy for accelerating growth and driving operational excellence. 

The firm saw a 204 percent increase in clinical services test volume year over year driven by increased offerings in several testing services.

Natera has focused on tapping into the average risk market for its suite of noninvasive prenatal assays, which it said is paying off. 

The company's revenues were driven by sales of its Panorama NIPT and Horizon carrier screening tests. 

The company said revenues from sales of its software services rose more than 250 percent during the quarter.